Studies of atherogenic lipoproteins using mass spectrometry-based lipidomics
Abstract
The prevalence of type 2 diabetes is increasing worldwide and is about to reach epidemic proportions. The disease is often associated with dyslipidemia which is characterized by an atherogenic lipoprotein profile including elevated serum triacylglycerol levels, low high-density lipoprotein levels and high levels of small low-density lipoproteins. Several large clinical studies have shown that this change in serum lipoprotein profiles constitutes a major cardiovascular risk factor, but the molecular mechanisms are still not completely understood. It has been proposed that the intrinsic properties of the particles, such as protein and lipid composition, might be responsible for the increased risk, mediated through an increased accumulation of lipoproteins in the artery wall, leading to atherosclerosis. The primary aim of this thesis was to isolate and, with a lipidomics approach, characterize the atherogenic lipoproteins from patients with type 2 diabetes. A secondary aim was to link compositional changes to atherosclerotic processes in vitro.
Initially, an ultracentrifugational method was developed for the isolation of lipoproteins at physiological settings. Then, in order to make a comprehensive lipid characterization of the lipoproteins, an analytical platform for lipidomics analyses was established. This platform consists of a normal-phase HPLC system with an evaporative light scattering detector that is used in combination with a hybrid quadrupole time-of-flight instrument, equipped with a chip-based nanoelectrospray interface.
By using this platform the atherogenic lipoproteins from patients participating in two major studies were characterized. The results revealed several alterations in the lipid and protein composition of the atherogenic lipoproteins isolated from patients with type 2 diabetes. Several of these alterations could, by the use of different in vitro systems, be linked mechanistically to proatherogenic processes such as lipoprotein retention and tissue inflammation. We also showed that changes in lipoprotein lipid composition were mainly associated with dyslipidemia.
Parts of work
I. Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, Fagerberg B and Camejo G. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. Journal of Lipid Research; 2008; 49(2): 481-490. ::PMID::18025001 II. Hiukka A, Ståhlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Mattson Hultén L, Wiklund O, Orešič M, Olofsson SO, Taskinen MR, Ekroos K and Borén J. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009; 58(9): 2018-2026. ::PMID::19502413 III. Ståhlman M, Pham H, Adiels M, Mitchell TW, Blanksby SJ, Fagerberg B, Ekroos K and Borén J. Lipidomics of apoB-containing lipoproteins reveal that dyslipidemia is associated with alterations in molecular lipids leading to increased proinflammatory properties.
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Medicine. Department of Molecular and Clinical Medicine
Disputation
Fredagen den 24 september 2010, kl 09.00 Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Date of defence
2010-09-24
marcus.stahlman@wlab.gu.se
Date
2010-09-03Author
Ståhlman, Marcus
Keywords
lipids
lipoproteins
atherogenesis
lipidomics
type 2 diabetes
mass spectrometry
Publication type
Doctoral thesis
ISBN
978-91-628-8150-4
Language
eng